Home ETF List About

Portfolio Holdings Detail for ISIN IE00BHZPJ890
Stock Name / FundiShares MSCI USA ESG Enhanced UCITS ETF USD (Dist)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity Type
Entity LEI 549300ZP07LMR36K1T02
ETF TickerEEDG(GBP) LSE
ETF TickerEEDS(USD) LSE
ETF TickerEEDG.LS(GBP) CXE
ETF TickerEEDS.LS(USD) CXE
ETF TickerOM3L.DE(EUR) CXE
ETF TickerEEDG.L(GBP) LSE
ETF TickerEEDS.L(GBP) LSE

Holdings detail for RPRX

Stock NameRoyalty Pharma Plc
TickerRPRX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINGB00BMVP7Y09
LEI549300FGFN7VOK8BZR03

Show aggregate RPRX holdings

News associated with RPRX

Royalty Pharma Expects At Least Mid-teens Average Annual Total Shareholder Return Over 2025-2030.
(RTTNews) - Royalty Pharma plc (RPRX) Thursday said it will host an Investor Day today, where senior executives will provide updates on the company's strategies aimed at driving shareholder value creation. - 2025-09-11 08:35:29
Maryland State Retirement & Pension System Trims Stock Position in Royalty Pharma PLC (NASDAQ:RPRX)
Maryland State Retirement & Pension System lessened its position in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 18.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 18,291 shares of the biopharmaceutical company’s stock after selling 4,133 shares during the quarter. […] - 2025-08-15 05:22:58
PNC Financial Services Group Inc. Acquires 859 Shares of Royalty Pharma PLC (NASDAQ:RPRX)
PNC Financial Services Group Inc. boosted its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 7.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,665 shares of the biopharmaceutical company’s stock after purchasing an additional […] - 2025-08-15 04:48:59
Blair William & Co. IL Invests $212,000 in Royalty Pharma PLC (NASDAQ:RPRX)
Blair William & Co. IL bought a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,801 shares of the biopharmaceutical company’s stock, valued at approximately $212,000. A number of other hedge […] - 2025-08-13 07:56:48
Deutsche Bank AG Sells 1,775,038 Shares of Royalty Pharma PLC (NASDAQ:RPRX)
Deutsche Bank AG lessened its holdings in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 55.6% during the 1st quarter, Holdings Channel.com reports. The firm owned 1,414,926 shares of the biopharmaceutical company’s stock after selling 1,775,038 shares during the period. Deutsche Bank AG’s holdings in Royalty Pharma were worth $44,047,000 as of its most recent […] - 2025-08-13 05:54:50
Charles Schwab Investment Management Inc. Has $97.20 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX)
Charles Schwab Investment Management Inc. cut its holdings in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 0.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 3,122,531 shares of the biopharmaceutical company’s stock after selling 9,097 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Royalty Pharma were worth $97,204,000 as […] - 2025-08-13 05:10:46
Royalty Pharma (NASDAQ:RPRX) Raised to Buy at Wall Street Zen
Royalty Pharma (NASDAQ:RPRX – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday. A number of other equities research analysts also recently weighed in on the company. Morgan Stanley boosted their target price on Royalty Pharma from $51.00 […] - 2025-08-11 03:50:55
Allianz Asset Management GmbH Has $6.03 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX)
Allianz Asset Management GmbH reduced its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 64.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 193,591 shares of the biopharmaceutical company’s stock after selling 356,968 shares during the period. Allianz […] - 2025-07-28 07:00:47
Edgestream Partners L.P. Invests $659,000 in Royalty Pharma PLC (NASDAQ:RPRX)
Edgestream Partners L.P. acquired a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 21,158 shares of the biopharmaceutical company’s stock, valued at approximately $659,000. Other hedge funds and other institutional investors also […] - 2025-07-20 05:24:59
Cerity Partners LLC Boosts Stake in Royalty Pharma PLC (NASDAQ:RPRX)
Cerity Partners LLC raised its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 786.3% during the 1st quarter, Holdings Channel reports. The fund owned 153,846 shares of the biopharmaceutical company’s stock after purchasing an additional 136,487 shares during the period. Cerity Partners LLC’s holdings in Royalty Pharma were worth $4,789,000 as […] - 2025-07-17 05:00:57
Xponance Inc. Acquires 1,437 Shares of Royalty Pharma PLC (NASDAQ:RPRX)
Xponance Inc. raised its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 3.7% in the first quarter, HoldingsChannel.com reports. The firm owned 40,133 shares of the biopharmaceutical company’s stock after buying an additional 1,437 shares during the period. Xponance Inc.’s holdings in Royalty Pharma were worth $1,249,000 as of its most […] - 2025-07-16 05:48:56
M&T Bank Corp Buys 5,500 Shares of Royalty Pharma PLC (NASDAQ:RPRX)
M&T Bank Corp raised its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 23.4% in the 1st quarter, Holdings Channel reports. The firm owned 28,967 shares of the biopharmaceutical company’s stock after acquiring an additional 5,500 shares during the period. M&T Bank Corp’s holdings in Royalty Pharma were worth $902,000 at […] - 2025-07-15 06:23:30
Teacher Retirement System of Texas Cuts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX)
Teacher Retirement System of Texas cut its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 10.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,364 shares of the biopharmaceutical company’s stock after selling 12,028 shares during the […] - 2025-07-09 05:33:01
Allspring Global Investments Holdings LLC Boosts Stake in Royalty Pharma PLC (NASDAQ:RPRX)
Allspring Global Investments Holdings LLC boosted its position in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 4.0% in the first quarter, Holdings Channel.com reports. The institutional investor owned 561,724 shares of the biopharmaceutical company’s stock after acquiring an additional 21,729 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Royalty […] - 2025-07-03 06:09:03
11,210 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Acquired by Kentucky Retirement Systems Insurance Trust Fund
Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) in the first quarter, HoldingsChannel reports. The firm acquired 11,210 shares of the biopharmaceutical company’s stock, valued at approximately $349,000. Other hedge funds also recently bought and sold shares of the company. Louisbourg Investments Inc. […] - 2025-06-26 05:42:57
After Hours Most Active for Jun 24, 2025 : SNAP, NVDA, CMCSA, PLTR, INTC, SPR, AUR, RPRX, KVUE, MPW, GM, WMT
The NASDAQ 100 After Hours Indicator is down -.81 to 22,189.71. The total After hours volume is currently 173,627,396 shares traded.The following are the most active stocks for the after hours session: Snap Inc. (SNAP) is unchanged at $8.32, with 14,501,942 shares traded. SNAP's - 2025-06-24 17:24:56
Manning & Napier Advisors LLC Sells 44,505 Shares of Royalty Pharma PLC (NASDAQ:RPRX)
Manning & Napier Advisors LLC lessened its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 54.9% during the first quarter, HoldingsChannel.com reports. The firm owned 36,549 shares of the biopharmaceutical company’s stock after selling 44,505 shares during the quarter. Manning & Napier Advisors LLC’s holdings in Royalty Pharma were worth $1,138,000 […] - 2025-06-24 05:20:57
After Hours Most Active for Jun 11, 2025 : PLTR, NVDA, AMZN, AAPL, RPRX, MCHPP
The NASDAQ 100 After Hours Indicator is up 14.32 to 21,875.12. The total After hours volume is currently 131,070,110 shares traded.The following are the most active stocks for the after hours session: Palantir Technologies Inc. (PLTR) is +0.25 at $136.64, with 5,538,416 shares t - 2025-06-11 17:24:56
Rhumbline Advisers Has $14.01 Million Position in Royalty Pharma plc (NASDAQ:RPRX)
Rhumbline Advisers lowered its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 0.9% during the first quarter, HoldingsChannel reports. The firm owned 449,964 shares of the biopharmaceutical company’s stock after selling 4,184 shares during the quarter. Rhumbline Advisers’ holdings in Royalty Pharma were worth $14,007,000 as of its most recent SEC […] - 2025-06-09 05:24:51
Lazard Asset Management LLC Reduces Holdings in Royalty Pharma plc (NASDAQ:RPRX)
Lazard Asset Management LLC lowered its stake in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 4.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,457 shares of the biopharmaceutical company’s stock after selling 1,130 shares during the quarter. Lazard Asset […] - 2025-05-22 05:46:49
Royalty Pharma plc (NASDAQ:RPRX) Receives Average Rating of “Buy” from Brokerages
Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) has received a consensus recommendation of “Buy” from the five research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. […] - 2025-05-22 04:50:51
Captrust Financial Advisors Sells 14,499 Shares of Royalty Pharma plc (NASDAQ:RPRX)
Captrust Financial Advisors reduced its position in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 49.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 14,829 shares of the biopharmaceutical company’s stock after selling 14,499 shares during the quarter. Captrust Financial Advisors’ holdings in Royalty Pharma were worth $378,000 as of […] - 2025-05-20 04:52:44
Analysts Predict 10% Gains Ahead For The Holdings of EUSA
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-19 07:59:43
Royalty Pharma (NASDAQ:RPRX) Raised to “Buy” at StockNews.com
Royalty Pharma (NASDAQ:RPRX – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Monday. Separately, Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. One equities research analyst has rated […] - 2025-05-14 02:14:45
Stifel Financial Corp Lowers Stake in Royalty Pharma plc (NASDAQ:RPRX)
Stifel Financial Corp reduced its stake in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 11.4% in the fourth quarter, Holdings Channel reports. The firm owned 17,152 shares of the biopharmaceutical company’s stock after selling 2,200 shares during the period. Stifel Financial Corp’s holdings in Royalty Pharma were worth $438,000 at the end […] - 2025-05-13 04:50:58
Prudential Financial Inc. Has $488,000 Stake in Royalty Pharma plc (NASDAQ:RPRX)
Prudential Financial Inc. lowered its holdings in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 4.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 18,360 shares of the biopharmaceutical company’s stock after selling 955 shares during the period. Prudential Financial Inc.’s holdings in Royalty Pharma were worth $488,000 at the end of the […] - 2025-04-10 05:01:02
American Century Companies Inc. Boosts Holdings in Royalty Pharma plc (NASDAQ:RPRX)
American Century Companies Inc. grew its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 5.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 67,160 shares of the biopharmaceutical company’s stock after buying an additional 3,671 shares […] - 2025-04-10 04:26:56
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by JPMorgan Chase & Co.
JPMorgan Chase & Co. lifted its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 8.2% in the 4th quarter, Holdings Channel reports. The firm owned 1,395,242 shares of the biopharmaceutical company’s stock after purchasing an additional 105,824 shares during the quarter. JPMorgan Chase & Co.’s holdings in Royalty Pharma were worth $35,593,000 at […] - 2025-04-08 04:44:55
Schroder Investment Management Group Sells 354,483 Shares of Royalty Pharma plc (NASDAQ:RPRX)
Schroder Investment Management Group lowered its stake in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 64.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 196,359 shares of the biopharmaceutical company’s stock after selling 354,483 shares during the quarter. Schroder Investment Management […] - 2025-04-06 05:29:08
Analysts Set Royalty Pharma plc (NASDAQ:RPRX) PT at $41.60
Shares of Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) have earned a consensus rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating […] - 2025-03-31 02:14:52

iShares MSCI USA ESG Enhanced UCITS ETF USD (Dist) RPRX holdings

DateNumber of RPRX Shares HeldBase Market Value of RPRX SharesLocal Market Value of RPRX SharesChange in RPRX Shares HeldChange in RPRX Base ValueCurrent Price per RPRX Share HeldPrevious Price per RPRX Share Held
2025-09-26 (Friday)858,158USD 30,069,856USD 30,069,856
2025-09-25 (Thursday)869,026USD 30,329,007USD 30,329,007
2025-09-24 (Wednesday)863,216USD 30,877,236USD 30,877,236
2025-09-18 (Thursday)822,716RPRX holding increased by 2968USD 29,395,643RPRX holding increased by 179824USD 29,395,6432,968USD 179,824 USD 35.73 USD 35.64
2025-09-17 (Wednesday)819,748RPRX holding increased by 4730USD 29,215,819RPRX holding increased by 347881USD 29,215,8194,730USD 347,881 USD 35.64 USD 35.42
2025-09-16 (Tuesday)815,018USD 28,867,938RPRX holding increased by 220055USD 28,867,9380USD 220,055 USD 35.42 USD 35.15
2025-09-15 (Monday)815,018USD 28,647,883USD 28,647,883
2025-09-12 (Friday)812,663USD 29,548,427USD 29,548,427
2025-09-11 (Thursday)810,861RPRX holding decreased by -5968USD 29,758,599RPRX holding increased by 205726USD 29,758,599-5,968USD 205,726 USD 36.7 USD 36.18
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RPRX by Blackrock for IE00BHZPJ890

Show aggregate share trades of RPRX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-18BUY2,968 35.730* 31.59
2025-09-17BUY4,730 35.640* 31.57
2025-09-11SELL-5,968 36.700* 31.51 Profit of 188,080 on sale
2025-09-10BUY1,088 36.180* 31.49
2025-09-09BUY1,430 36.500* 31.46
2025-08-27BUY840 36.060* 31.41
2025-08-21BUY210 36.310* 31.35
2025-08-19BUY645 36.000* 31.29
2025-07-21BUY109 35.650* 31.26
2025-07-18BUY4,975 35.590* 31.24
2025-07-17BUY654 35.470* 31.21
2025-07-16BUY9,553 35.600* 31.19
2025-07-15BUY5,995 36.510* 31.15
2025-07-03SELL-840 36.370* 31.09 Profit of 26,114 on sale
2025-07-02SELL-6,822 36.190* 31.06 Profit of 211,865 on sale
2025-06-30SELL-139 36.030* 31.02 Profit of 4,312 on sale
2025-06-27BUY436 35.870* 30.99
2025-06-26BUY218 35.270* 30.97
2025-06-25BUY436 35.910* 30.94
2025-06-24SELL-327 36.140* 30.90 Profit of 10,105 on sale
2025-06-17SELL-440 34.560* 30.77 Profit of 13,538 on sale
2025-06-13SELL-198 34.840* 30.71 Profit of 6,081 on sale
2025-06-12BUY315 35.270* 30.68
2025-06-06SELL-1,526 33.780* 30.60 Profit of 46,688 on sale
2025-06-05SELL-2,398 33.750* 30.57 Profit of 73,314 on sale
2025-06-04SELL-3,074 33.440* 30.55 Profit of 93,919 on sale
2025-06-03BUY636 33.290* 30.53
2025-06-02SELL-186 33.260* 30.51 Profit of 5,676 on sale
2025-05-30BUY1,166 32.880* 30.50
2025-05-29SELL-663 32.640* 30.48 Profit of 20,209 on sale
2025-05-28SELL-436 32.630* 30.46 Profit of 13,283 on sale
2025-05-23SELL-1,932 32.450* 30.42 Profit of 58,768 on sale
2025-05-22BUY106 32.310* 30.40
2025-05-21SELL-545 32.830* 30.39 Profit of 16,560 on sale
2025-05-20BUY2,332 33.090* 30.36
2025-05-16SELL-981 34.020* 30.31 Profit of 29,730 on sale
2025-05-15BUY115 33.120* 30.28
2025-05-14BUY1,920 32.290* 30.27
2025-05-13BUY6,934 32.820* 30.25
2025-05-12BUY5,565 33.350* 30.22
2025-05-09BUY1,785 33.150* 30.20
2025-05-08SELL-1,744 33.100* 30.17 Profit of 52,624 on sale
2025-05-07BUY4,935 32.750* 30.15
2025-05-06BUY1,155 32.110* 30.14
2025-05-02SELL-190 32.890* 30.09 Profit of 5,717 on sale
2025-05-01SELL-105 32.480* 30.07 Profit of 3,157 on sale
2025-04-29BUY4 32.710* 30.02
2025-04-28SELL-14,573 32.540* 30.00 Profit of 437,190 on sale
2025-04-25SELL-210 32.200* 29.98 Profit of 6,296 on sale
2025-04-24SELL-3,255 32.030* 29.96 Profit of 97,527 on sale
2025-04-23SELL-1,155 31.690* 29.95 Profit of 34,588 on sale
2025-04-22SELL-756 32.190* 29.93 Profit of 22,624 on sale
2025-04-16SELL-4,095 32.190* 29.83 Profit of 122,167 on sale
2025-04-11BUY2,077 31.950* 29.76
2025-04-10BUY654 31.210* 29.75
2025-04-09BUY1,075 32.270* 29.72
2025-04-08SELL-2,997 30.850* 29.71 Profit of 89,050 on sale
2025-04-07BUY2,051 31.030* 29.70
2025-04-04BUY4,451 31.110* 29.69
2025-04-02BUY1,817 31.280* 29.67
2025-04-01BUY872 31.170* 29.65
2025-03-31SELL-4,644 31.130* 29.64 Profit of 137,637 on sale
2025-03-28SELL-440 31.370* 29.62 Profit of 13,032 on sale
2025-03-26BUY110 31.560* 29.58
2025-03-25BUY330 33.760* 29.53
2025-03-24BUY660 33.750* 29.48
2025-03-21BUY16,940 33.700* 29.44
2025-03-20BUY220 33.500* 29.39
2025-03-19SELL-3,074 33.410* 29.34 Profit of 90,201 on sale
2025-03-17SELL-220 33.020* 29.25 Profit of 6,435 on sale
2025-03-14SELL-440 32.770* 29.21 Profit of 12,853 on sale
2025-03-13SELL-106 32.680* 29.17 Profit of 3,092 on sale
2025-03-12SELL-700 32.850* 29.12 Profit of 20,387 on sale
2025-03-11BUY110 32.460* 29.08
2025-03-06BUY6,510 33.280* 28.93
2025-03-05SELL-537 33.770* 28.87 Profit of 15,502 on sale
2025-03-03BUY327 33.860* 28.74
2025-02-28BUY2,189 33.640* 28.68
2025-02-27SELL-2,140 33.370* 28.61 Profit of 61,230 on sale
2025-02-26SELL-27,499 33.380* 28.55 Profit of 784,982 on sale
2025-02-25SELL-1,887 33.690* 28.47 Profit of 53,729 on sale
2025-02-24BUY2,675 33.800* 28.40
2025-02-21BUY1,399 33.420* 28.32
2025-02-20BUY258 33.330* 28.25
2025-02-19BUY222 32.590* 28.19
2025-02-18SELL-1,201 32.850* 28.12 Profit of 33,767 on sale
2025-02-14BUY333 32.360* 27.98
2025-02-13SELL-222 32.460* 27.91 Profit of 6,196 on sale
2025-02-12SELL-4,218 32.340* 27.84 Profit of 117,430 on sale
2025-02-10SELL-44 31.720* 27.70 Profit of 1,219 on sale
2025-02-06BUY607 31.400* 27.57
2025-02-05SELL-1,665 31.450* 27.50 Profit of 45,789 on sale
2025-02-03BUY196 31.330* 27.36
2025-01-30SELL-2,247 31.590* 27.20 Profit of 61,126 on sale
2025-01-29SELL-16 31.950* 27.11 Profit of 434 on sale
2025-01-28SELL-1,479 31.940* 27.02 Profit of 39,959 on sale
2025-01-27BUY666 31.720* 26.92
2025-01-24BUY1,177 31.060* 26.84
2025-01-23BUY1,177 30.620* 26.76
2024-12-09BUY220 26.010* 26.80
2024-12-06BUY3,410 25.910* 26.82
2024-12-04BUY2,530 26.100* 26.85
2024-12-03BUY1,466 26.340* 26.86
2024-12-02BUY3,300 26.430* 26.87
2024-11-29BUY330 26.660* 26.88
2024-11-27BUY109 26.600* 26.89
2024-11-26SELL-3,736 26.290* 26.91 Profit of 100,527 on sale
2024-11-25BUY637,712 26.470* 26.92
2024-11-22SELL-32 26.430* 26.93 Profit of 862 on sale
2024-11-21BUY762 26.400* 26.95
2024-11-19SELL-163 26.010* 27.00 Profit of 4,401 on sale
2024-11-18BUY340 25.800* 27.04
2024-11-12BUY17 26.000* 27.08
2024-11-08BUY47 26.210* 27.17
2024-11-08BUY47 26.210* 27.17
2024-11-07BUY1,232 26.520* 27.22
2024-11-07BUY1,232 26.520* 27.22
2024-11-06BUY34 26.640* 27.27
2024-11-06BUY34 26.640* 27.27
2024-11-05SELL-90 27.540* 27.24 Profit of 2,452 on sale
2024-11-05SELL-90 27.540* 27.24 Profit of 2,452 on sale
2024-11-04SELL-576 27.200* 27.25 Profit of 15,694 on sale
2024-11-04SELL-576 27.200* 27.25 Profit of 15,694 on sale
2024-11-01SELL-170 27.100* 27.26 Profit of 4,635 on sale
2024-11-01SELL-170 27.100* 27.26 Profit of 4,635 on sale
2024-10-31BUY102 27.000* 27.30
2024-10-31BUY102 27.000* 27.30
2024-10-30SELL-684 27.190* 27.31 Profit of 18,683 on sale
2024-10-30SELL-684 27.190* 27.31 Profit of 18,683 on sale
2024-10-29SELL-648 27.150* 27.33 Profit of 17,709 on sale
2024-10-28BUY54 27.260* 27.34
2024-10-28BUY54 27.260* 27.34
2024-10-25BUY1,152 26.950* 27.44
2024-10-25BUY1,152 26.950* 27.44
2024-10-24BUY152 27.280* 27.49
2024-10-24BUY152 27.280* 27.49
2024-10-23SELL-24 27.360* 27.56 Profit of 661 on sale
2024-10-23SELL-24 27.360* 27.56 Profit of 661 on sale
2024-10-22BUY133 27.370* 27.75
2024-10-22BUY133 27.370* 27.75
2024-10-21SELL-1,330 27.750* 0.00
2024-10-21SELL-1,330 27.750* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RPRX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19877,43501,269,34869.1%
2025-09-18854,1562551,225,70969.7%
2025-09-17890,42801,130,88978.7%
2025-09-16849,69101,371,04262.0%
2025-09-151,310,0518751,800,47672.8%
2025-09-121,066,1208001,339,29279.6%
2025-09-111,220,1202831,532,65679.6%
2025-09-101,195,1197901,440,33383.0%
2025-09-091,259,8539241,521,80482.8%
2025-09-081,967,2801,0943,312,54759.4%
2025-09-052,792,92604,789,48758.3%
2025-09-04649,49701,396,64246.5%
2025-09-03741,51103,964,24418.7%
2025-09-021,164,4616211,836,12263.4%
2025-08-29568,8486441,099,44151.7%
2025-08-28343,4431,229665,67251.6%
2025-08-27718,529151,134,79763.3%
2025-08-26376,8063,158782,11648.2%
2025-08-25523,36001,666,11631.4%
2025-08-22416,9751,403983,55642.4%
2025-08-21515,9061789,60565.3%
2025-08-20668,9345571,359,61949.2%
2025-08-19282,3631,211801,13935.2%
2025-08-18470,777713735,14364.0%
2025-08-15370,8860849,95543.6%
2025-08-14437,27101,270,82534.4%
2025-08-13450,93002,187,21920.6%
2025-08-12378,7083211,366,73627.7%
2025-08-11566,6033221,321,77142.9%
2025-08-08732,3041,1411,058,55269.2%
2025-08-07637,7791411,478,11943.1%
2025-08-06968,026951,335,30672.5%
2025-08-05817,147971,153,95670.8%
2025-08-04562,562677830,96467.7%
2025-08-01356,771847641,24655.6%
2025-07-31550,713210657,91283.7%
2025-07-30529,655432816,35164.9%
2025-07-29600,85925752,37279.9%
2025-07-28682,7281,073824,97582.8%
2025-07-25351,99350514,20168.5%
2025-07-24396,41057557,22971.1%
2025-07-23289,2172,996787,22036.7%
2025-07-22460,4210666,17169.1%
2025-07-21489,8451,682693,05470.7%
2025-07-18355,3760587,43460.5%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.